Thinking and memory with extended-release tacrolimus in kidney transplant
Part of Brain & nervous system, Mental health clinical trials.
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least one year past your latest kidney transplant
- You currently take the immediate-release form of tacrolimus (brand names like Prograf) and your levels are stable
- Your kidney function has been stable over the last three months
- You speak English or Spanish and have regular follow-up at Massachusetts General Hospital
- You do not have serious memory problems, Parkinson's disease, active cancer, severe liver disease, or uncontrolled depression or anxiety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This study observes older kidney transplant patients (65+) who take a specific anti-rejection drug called tacrolimus once a day. It looks at their long-term outcomes to help improve care for people in this age group.
Hear when a new Kidney Transplant Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.